ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
Guardado en:
Autores principales: | Ahmed Daoud, Hatem Ali, Vinaya Rao, Vinayak Rohan, Karim Soliman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Taylor & Francis Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/148c421b864c4ce3b4bc13adbd30bf57 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
[9] α-Blockers and acute urinary retention
por: Samir Bouras
Publicado: (2018) -
Roseomonas mucosa-Induced Peritonitis in a Patient Undergoing Continuous Cycler Peritoneal Dialysis: Case Report and Literature Analysis
por: Sasmit Roy, et al.
Publicado: (2021) -
Understand the difference between clinical measured ultrafiltrationand real ultrafiltration in peritoneal dialysis
por: Zanzhe Yu, et al.
Publicado: (2021) -
A case of Sphingomonas paucimobilis causing peritoneal dialysis-associated peritonitis and review of the literature
por: Chiharu Kinoshita, et al.
Publicado: (2021) -
Effect of symptom-based alpha-blocker treatment on lower urinary tract symptoms in women: systematic review and meta-analysis
por: Tae Wook Kang, et al.
Publicado: (2021)